Author

T. Chen

Institutions: National Cheng Kung University Hospital, National Cheng Kung University

Observed institutions: National Cheng Kung University Hospital, National Cheng Kung University

OpenAlex ID: A5047823830

A PHASE 3 STUDY OF ACALABRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN ELDERLY (AGED ≥65 Years) TREATMENT‐NAIVE PATIENTS WITH MANTLE CELL LYMPHOMA

2019 · M. Wang, D. Belada, et al. · Hematological Oncology · 2

Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)

2017 · T. Zhang, M. Harrison, et al. · Annals of Oncology · 2

618 | Sequential Btk Inhibitor Therapy in Relapsed/refractory Mantle Cell Lymphoma: Real‐world Outcomes and Attrition Rates—final Report From the Asia‐pacific Registry

2025 · H. Cho, D. H. Yoon, et al. · Hematological Oncology

Treatment Patterns in Patients With Mantle Cell Lymphoma: Updated Report of the Asia‐pacific Multinational Retrospective Registry Study

2023 · W. S. Kim, D. H. Yoon, et al. · Hematological Oncology

Works count: 4

Citation count: 4

H-index: 2

I10-index: